Elicio Therapeutics, Inc.
ELTXNasdaq
$3.11
↓ -2.8%Jul 17 close · end-of-day
Price
1Y↓ -65.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$56.6M
Enterprise Value
$51.2M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$40.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
2796.5%
ROIC
—
Debt / Equity
-6.6
Net Cash
$5.5M
Return 1Y
-66.6%
Company profile
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company was formerly known as VEDANTRA PHARMACEUTICALS, INC. and changed its name to Elicio Therapeutics Inc. on September 18, 2019. The company was incorporated in 2011 and is headquartered in Boston, Massachusetts.
- CEO
- Robert T. Connelly
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 23
- Headquarters
- Massachusetts
- Website
- elicio.com
Management & directors
- Connelly RobertCEO, President and Director
- Demuth PeterChief Scientific Officer
- Haqq ChristopherSee Remarks
- Shah PreetamSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
ELTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.65↓ -25.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.9M | $28.3M | $2.3M | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$55.3M | -$39.3M | -$23.7M | -$35.7M | -$45.0M | -$37.7M |
| Net income | -$80.1M | -$54.6M | -$28.2M | -$35.2M | -$51.9M | -$39.6M |
| Diluted EPS | -$5.43 | -$1.93 | -$89.27 | -$6.96 | -$4.25 | -$2.58 |
| Operating cash flow | -$22.9M | -$52.6M | -$22.2M | -$32.7M | -$37.1M | -$37.0M |
| Free cash flow | -$22.9M | -$53.0M | -$22.8M | -$32.8M | -$37.2M | -$37.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1919.2% | -138.8% | -1031.4% | — | — | — |
| Net margin | -2781.5% | -192.8% | -1225.9% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$10.9M | -$10.3M | -$13.5M | -$10.7M | -$10.1M | -$8.0M | -$8.8M | -$10.6M |
| Net income | -$7.2M | -$18.8M | -$14.0M | -$11.2M | -$10.6M | -$10.1M | -$7.7M | -$11.8M |
| Diluted EPS | -$0.64 | -$1.39 | -$1.07 | -$0.87 | -$0.66 | -$0.60 | -$0.45 | -$0.65 |
| Operating cash flow | -$8.9M | -$7.3M | -$8.7M | -$10.1M | -$8.9M | -$11.1M | -$6.8M | -$11.6M |
| Free cash flow | -$9.0M | -$7.3M | -$8.8M | — | — | -$11.1M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 2, 2026
- 18d agoWall Street Set to Open Higher in Thursday Trading; US Adds Only 57,000 Jobs in Junefinance.yahoo.com
- 18d agoAnother Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointmentstocktwits.com
- 18d agoElicio Therapeutics Announces Pricing of $15 Million Registered Direct Offeringfinance.yahoo.com
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-02 | Connelly Robert· CEO, President and Director | Award | 73,600 | $0.00 | $0.00 | filing |
| 2026-02-02 | Shah Preetam· See Remarks | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-02-02 | DeMuth Peter· Chief Scientific Officer | Award | 20,800 | $0.00 | $0.00 | filing |
| 2026-02-02 | Haqq Christopher· See Remarks | Award | 25,400 | $0.00 | $0.00 | filing |
| 2025-12-09 | DeMuth Peter· Chief Scientific Officer | Option exercise | 362 | $4.41 | $1,596.42 | filing |
Latest 5 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.